Journal article
Evaluation of cardiovascular biomarkers In HIV-infected patients switching to abacavir or tenofovir based therapy
Thomas A Rasmussen, Martin Tolstrup, Jesper Melchjorsen, Christian A Frederiksen, Ulla S Nielsen, Bente L Langdahl, Lars Ostergaard, Alex L Laursen
BMC INFECTIOUS DISEASES | BIOMED CENTRAL LTD | Published : 2011
Abstract
BACKGROUND: Our objective was to evaluate and compare the effect of abacavir on levels of biomarkers associated with cardiovascular risk. METHODS: In an open-label randomized trial, HIV-infected patients were randomized 1:1 to switch from zidovudine/lamivudine to abacavir/lamivudine or tenofovir/emtricitabine. In the present analysis, we measured levels of interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular adhesion molecule-1 (sVCAM-1), E-selectin, and myeloperoxidase (MPO) at baseline and 4, 12, and 48 weeks after randomization. D-dimer and fasting lipids were measured at baseline and weeks 12 and 48. Lev..
View full abstractGrants
Awarded by GlaxoSmithKline
Funding Acknowledgements
The study was supported by grants from GlaxoSmithKline and the Aarhus University Hospital, Skejby Research Foundation. We thank the study participants for their involvement in the study and the study nurses, Iben Rose Loftsheim and Inge Vejlgaard Arbs, for an excellent effort as trial site coordinators. We thank the medical laboratory technicians Erik Hagen Nielsen and Lene Svinth Jonke for technical assistance in processing and handling of blood samples and analyses.Lars Ostergaard has received consultancy and speaker's fee from: Abbott, MSD, Pfizer, Bristol-Meyer Squibb, GlaxoSmithKline, ViiV Healthcare, Gilead, and Tibotec. Alex L Laursen has served on the advisory board for GlaxoSmithKline, Gilead, and Janssen. GlaxoSmithKline supported this study with a grant of DKR 100.000.